Aristotle University Of Thessaloniki (AUTH)
Μελέτη εργαστηριακών δεικτών δυσλειτουργίας του ενδοθηλίου σχετιζόμενων με την αιμόσταση σε ασθενείς με COVID-19 λοίμωξη
Abstract
dc:descriptionCOVID-19 (Coronavirus Disease 2019) is a clinical syndrome caused by the SARS-CoV-2 virus (Severe Acute Respiratory Syndrome Coronavirus-2). This virus is identified as the agent responsible for a multisystem disease, with primary manifestations including acute respiratory syndrome, endotheliopathy, and immunothrombosis. These symptoms increase the risk of both micro- and macrothrombosis, and endothelial dysfunction plays a crucial role in the progression of the disease. Venous thrombosis, pulmonary embolism, and stroke are a few of the thrombotic issues that may occur as a result. These issues are an essential component of the morbidity and mortality rates associated with COVID-19. The disease is exacerbated, and further research is needed to explain the basic pathological physiological mechanisms and to identify reliable biomarkers for early diagnosis and more precise clinical management. This study explores the prognostic significance of endothelial dysfunction markers related to hemostasis, including thrombomodulin, P-selectin, angiopoietin-2 (Ang-2), plasminogen activator inhibitor-1 (PAI-1), von Willebrand factor antigen (VWF: Ag), and von Willebrand factor co-reconstitution factor (VWF: RCo), as well as platelet microvesicles (PMPs), concerning disease severity in COVID-19 patients. A cross-sectional case-control study was conducted with 90 patients who had been confirmed to have COVID-19. Participants were divided into three groups: those hospitalized in the ICU, those outside the ICU, and asymptomatic, non-hospitalized individuals (control group). The study's originality lies in its systematic and simultaneous evaluation of a broad range of endothelial damage markers across different patient categories. Hemostasis markers were assessed through chronometric and coagulation tests, while the biomarkers PAI-1, thrombomodulin, and P-selectin were evaluated using enzyme-linked immunosorbent assay (ELISA). VWF: Ag and VWF: RCo biomarkers were analyzed using immunoenzymatic assays, and PMPs were assessed by flow cytometry. Statistical analysis included both parametric and non-parametric tests, as well as logistic regression and ROC analysis. Statistically significant differences were observed in the levels of the examined markers between the groups. Specifically, the biomarkers thrombomodulin, PAI-1, Ang-1, Ang-2, and PMPs showed significant differences in ICU patients compared to the other groups. Additionally, an increase was noted in markers such as P-selectin, D-dimer, factor VIII (FVIII), VWF: Ag, VWF: RCo, the VWF: RCo/VWF: Ag ratio, and the Ang-2/Ang-1 ratio.Furthermore, the Ang-2/Ang-1 ratio and P-selectin were very effective in predicting outcomes in all studies, especially in predicting hospital admissions. P-selectin has emerged as the most accurate biomarker for diagnosis and has proved its usefulness in determining the extent of a disease. Its involvement in COVID-19-associated endotheliopathy highlights a promising avenue for the development of novel therapeutic strategies. Additionally, P-selectin is a promising therapeutic target for various diseases, including diabetes, atherosclerosis, hypertension, and cancer. In general, biomarkers that indicate endothelial dysfunction have a significant predictive value for assessing the risk of thrombosis in COVID-19 patients. Incorporation inclinical practicecan improveearly identification of high-risk individuals and facilitate targeted therapeuticinterventions. Developments in this area hold promise for enhancing clinical outcomes and increasing the accuracy of predicting disease progression. Ultimately, these insights are expected to enhance our understanding of the pathophysiological mechanisms underlying COVID-19-associated endotheliopathy, offering potential applications in risk stratification and therapeutic strategy formulation.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tsiatsiou, Panagiota
- Τσιάτσιου, Παναγιώτα
Subjects
dc:subject × 8Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/59837